Overview

A Study of the Effectiveness and Safety of Different Doses of Fluticasone Propionate Taken From a Dry Powder Inhaler in Adolescents and Adults Who Have Asthma That is Not Controlled by Asthma Medications Not Containing Steroids

Status:
Completed

Trial end date:
2013-07-01

Target enrollment:

Participant gender:

Summary

This is a randomized, double-blind, placebo- and open-label active controlled, parallel-group, multicenter, dose ranging study in male or female subjects ages 12 years and older with persistent asthma who are uncontrolled on non-steroidal therapy. The primary objective of this study is to evaluate the dose response, efficacy and safety of 4 different doses of fluticasone propionate delivered as Fluticasone Propionate DPI (Dry Powder Inhaler) when administered twice daily.

Phase:

Phase 2

Details

Lead Sponsor:

Teva Branded Pharmaceutical Products R&D, Inc.
Teva Pharmaceutical Industries

Collaborator:

PPD

Treatments:

Adrenergic Agonists
Albuterol
Fluticasone
Xhance